Skip to search formSkip to main contentSkip to account menu

BN 80915

Known as: BN-80915, BN80915 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

diflomotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
BACKGROUND BN80915 (diflomotecan) is an E-ring modified camptothecin analogue, which possesses greater lactone stability in… 
2004
2004
Oral absorption of diflomotecan, a new E-ring modified camptothecin analogue, administered as soft-gel capsule.
2045 Background: The E-ring modified camptothecin analogue diflomotecan (BN80915, Ipsen Group) is a new topoisomerase I inhibitor… 
2003
2003
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
PURPOSE Diflomotecan (BN80915) is an E-ring modified camptothecin analogue that possesses greater lactone stability in plasma… 
2001
2001
Pharmacologic aspects of new classes of anti-cancer agents: inhibitors of topoisomerase I or tubulin
textabstractMany processes involved in unregulated proliferation of cells are subject to antitumor therapy, inhibition of the… 
1999
1999
American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania.
No genuinely new targets or drugs were disclosed; instead, data about known therapeutic approaches and compounds were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)